#United States #New York #Class Action #The Gross Law Firm #Humacyte

Humacyte, Inc. Class Action Notice

Investors in Humacyte, Inc. (NASDAQ: HUMA) are being urged to reach out to The Gross Law Firm before January 17, 2025, in relation to possible claims arising from their investment. A notice issued by the law firm highlights that individuals who bought shares during a specified class period, from May 10, 2024, to October 17, 2024, may be eligible to participate in this action.

Allegations against Humacyte

The complaint against Humacyte alleges that during this period, the company provided materially misleading statements and did not disclose significant issues regarding its operations. Specifically, the allegations include:
1. Regulatory Non-compliance: The Durham, North Carolina facility allegedly failed to meet good manufacturing practices, including deficiencies in quality assurance and microbial testing.
2. FDA Approval Delays: There are claims that the FDA’s review process for Humacyte's biologics license application was hindered due to the company needing to address these regulatory non-compliances.
3. Business Misrepresentation: As a result of these operational risks, the assertions made by the company regarding its business, operational status, and financial prospects were found to be misleading.

Given these serious allegations, the law firm encourages affected investors to consider their rights and possible lead plaintiff appointment. It’s important to note that being appointed as a lead plaintiff is not mandatory for participating in any potential recovery.

Next Steps for Investors

Interested shareholders should not delay in submitting their claims by registering on the firm's website. By doing so, they will gain access to continuous updates and information regarding the status of the class action case. The deadline for seeking lead plaintiff status is set for January 17, 2025. Participation in this case does not incur any costs or obligations for the investors.

Why Contact The Gross Law Firm?

The Gross Law Firm is a nationally recognized class action law firm dedicated to defending the rights of investors affected by deceptive practices. Their commitment centers around ensuring that companies act responsibly and uphold their duties to shareholders. They aim to secure recoveries for investors who have suffered losses due to misleading statements or omissions by corporations.

Contact Information

To get in touch with The Gross Law Firm, investors can reach out at:

• - Address: 15 West 38th Street, 12th Floor, New York, NY 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

For those who wish to follow this case and understand their rights as shareholders of Humacyte, the deadline is fast approaching. Taking action sooner rather than later is crucial in ensuring that your rights are protected in this sensitive matter.